Search Result

Results for "

chronic nerve pain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Cyclin G-associated Kinase (GAK) (1) P2Y Receptor (1) SARS-CoV (1) Sodium Channel (1)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Targets Recommended: Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117626

LP-935509	AAK1 Cyclin G-associated Kinase (GAK) SARS-CoV	Infection Neurological Disease Inflammation/Immunology
LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC₅₀ of 3.3 nM and a K_i of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC₅₀=14 nM) and a modest inhibitor of GAK (IC₅₀=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .

HY-167855

MRS4833	P2Y Receptor	Inflammation/Immunology
MRS4833 (compound 15) is an orally active, potent, competitive P2Y₁₄R antagonist with IC₅₀=5.92 nM for hP2Y₁₄R and IC₅₀=4.8 nM for mP2Y₁₄R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

HY-116275

KRM-II-81	Others	Cancer
KRM-II-81 is a gamma-aminobutyric acid type A (GABAA) receptor ligand with analgesic, anxiolytic and anti-epileptic activities. KRM-II-81 exhibits positive allosteric modulation of GABAA receptors selective for the α2/3 subunit. KRM-II-81 reduces formalin-induced pain response after oral administration. KRM-II-81 significantly reduces pain behavior induced by chronic spinal nerve ligation. Analysis of KRM-II-81 showed that its plasma and brain concentrations were positively correlated with analgesic effects. The enhancement effect of KRM-II-81 on GABA current shows its key role in the analgesic mechanism. KRM-II-81 was less effective in respiratory depression, demonstrating its safety and tolerability .

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

Cat. No.	Product Name

HY-L139

Pain-Related Compound Library	2,082 compounds
Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot. MCE supplies a unique collection of 2,082 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Pain-Related Compound Library

2,082 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 2,082 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Cat. No.	Product Name	Target	Research Area

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.